Article
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2020
Seligmann J F, Elliott F, Richman S, Hemmings G, Brown S, Jacobs B, Williams C, Tejpar S, Barrett J H, Quirke P, Seymour M
Abstract excerpt
BACKGROUND: Primary tumour location (PTL) is being adopted by clinicians to guide treatment decisions in metastatic colorectal cancer (mCRC). Here we test PTL as a predictive marker for panitumumab efficacy, and examine its relationship with an extended biomarker profile. We also examine rectal tumours as a separate location. PATIENTS AND METHODS: mCRC patients from the second-line PICCOLO trial of irinotecan...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.